Morningstar - Walgreens Boots Alliance Inc (WBA) We Believe the Amazon/Berkshire/JP Partnership Will Not Disrupt the PMBs, MCOs, and Wholesalers

Report

Morningstar

Vishnu Lekraj

EUR 101.80 For Business Accounts Only

We Believe the Amazon/Berkshire/JP Partnership Will Not Disrupt the PMBs, MCOs, and Wholesalers

Amazon, Berkshire Hathaway, and JP Morgan Chase announced on Jan. 30 that the trio will form an independent healthcare company to help control healthcare costs for their U.S.-based employees, and while there could be some potential given the capital and clout of the three partners, we believe certain investors are underappreciating the moaty nature of the healthcare supply chain and the formidable competitive advantages that have insulated its major players. All potential new competitors would f...

30/01/2018 13 EN

Underlying

Walgreens Boots Alliance Inc

Walgreens Boots Alliance is a holding company. Through its subsidiaries, the company is engaged in retail and wholesale pharmacy. The company's operations are organized into three divisions, which are also its reportable segments: Retail Pharmacy USA; Retail Pharmacy International; and Pharmaceutical Wholesale. The Retail Pharmacy USA division has pharmacy-led health and beauty retail offerings. The Retail Pharmacy International division has pharmacy-led health and beauty retail businesses. The Pharmaceutical Wholesale division, which mainly operates under the Alliance Healthcare brand, supplies medicines, other healthcare products and related services to pharmacies, doctors, health centers and hospitals.

See profile

US9314271084 NASDAQ Stock Market United States

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Vishnu Lekraj

Other Reports on these Companies

Moody's Investors Service

Moody's Ratings places Walgreens' ratings under review for downgrade following agreement to be acquired by Sycamore

Moody's Ratings ("Moody's") has today placed the ratings for Walgreens Boots Alliance, Inc. ("WBA") and its subsidiary Walgreen Co. (together combined referred to as "Walgreens") on review for downgrade. Ratings for downgrade include the company's Ba3 corporate family rating ("CFR"), its Ba3-PD pro...

EUR 154.04

March 7, 2025 March 7, 2025 1 EN

Vermilion Research

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

EUR 42.79

February 26, 2025 February 26, 2025 1 EN

Moody's Investors Service

Walgreens Boots Alliance, Inc.: Update following outlook change to negative

Our credit view of Walgreens reflects its weak credit metrics and cash flow, partially offset by its scale as the second largest US drugstore retailer and its commitment to debt repayment.

EUR 213.95

February 25, 2025 February 25, 2025 1 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

We Believe the Amazon/Berkshire/JP Partnership Will Not Disrupt the PMBs, MCOs, and Wholesalers

Moody's Ratings places Walgreens' ratings under review for downgrade following agreement to be acquired by Sycamore

Vermilion Booster Shots: Attractive bottom-fishing stocks

Walgreens Boots Alliance, Inc.: Update following outlook change to negative

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe